title: Hormone refractory prostatic cancer: the role of radiolabelled diphosphonates and growth factor inhibitors.
authors.affiliation: Department of Medicine, Memorial Sloan-Kettering Cancer Center, NY 10021.
authors.forename: H I
authors.initials: HI
authors.lastname: Scher
authors.forename: T
authors.initials: T
authors.lastname: Curley
authors.forename: S
authors.initials: S
authors.lastname: Yeh
authors.forename: W
authors.initials: W
authors.lastname: Tong
authors.forename: P V
authors.initials: PV
authors.lastname: O'Moore
authors.forename: S
authors.initials: S
authors.lastname: Larson
mesh_terms: D000818:Animals; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary*; D004285:Dogs; D004354:Drug Screening Assays, Antitumor; D012968:Etidronic Acid / Q000627:therapeutic use*; D006133:Growth Substances / Q000502:physiology; D006801:Humans; D008297:Male; D009363:Neoplasm Proteins / Q000502:physiology; D009942:Organometallic Compounds / Q000627:therapeutic use*; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D010166:Palliative Care; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000473:pathology*; D011868:Radioisotopes / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011877:Radionuclide Imaging; D012211:Rhenium / Q000627:therapeutic use*; D012493:Samarium / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013498:Suramin / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D006133:Growth Substances; D009363:Neoplasm Proteins; D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; D011868:Radioisotopes; D012493:Samarium; D013498:Suramin; D012211:Rhenium; C061972:samarium Sm-153 lexidronam; D017430:Prostate-Specific Antigen; D012968:Etidronic Acid